|
|
供应 AZD-6094(HMPL-504,Volitinib) /1313725-88-0 |
规 格: |
1 |
价 格: |
1/ |
数 量: |
1 |
交货地: |
|
发布时间: |
2016-07-28 |
有效期: |
255天 |
备 注: |
Savolitinib(Volitinib; AZD-6094; Volitinib) is an orally bioavailable inhibitor of the c-Met receptor tyrosine kinase(IC50= 5 nM) with potential antineoplastic activity.
IC50 value: 5 nM [1]
Target:
Volitinib demonstrated favorable pharmacokinetic properties in mice and good antitumor activities in the human glioma xenograft model in athymic nude mice.Volitinib selectively binds to and inhibits the activation of c-Met in an ATP-competitive manner, and disrupts c-Met signal transduction pathways. This may result in cell growth inhibition in tumors that overexpress the c-Met protein. C-Met encodes the hepatocyte growth factor receptor tyrosine kinase and plays an important role in tumor cell proliferation, survival, invasion, and metastasis, and tumor angiogenesis; this protein is overexpressed or mutated in a variety of cancers.
|
|
|